



(51) International Patent Classification:

C07K 16/00 (2006.01) *C07K 16/30* (2006.01)
A61K 47/68 (2017.01) *C07K 16/46* (2006.01)
A61K 49/00 (2006.01) *C12N 15/13* (2006.01)

(21) International Application Number:

PCT/CA2022/050453

(22) International Filing Date:

25 March 2022 (25.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/166,450 26 March 2021 (26.03.2021) US

(71) Applicant: **ZYMEWORKS INC.** [CA/CA]; Suite 800-114 East 4th Ave, Vancouver, British Columbia V5T 1G4 (CA).(72) Inventors: **RICH, James R.**; Suite 800- 114 East 4th Ave, Vancouver, British Columbia V5T 1G4 (CA). **SANCHES, Mario**; Suite 800- 114 East 4th Ave, Vancouver, British Columbia V5T 1G4 (CA). **DAS, Samir**; Suite 800- 114 East 4th Ave, Vancouver, British Columbia V5T 1G4 (CA).**FARBER, Patrick**; Suite 800- 114 East 4th Ave, Vancouver, British Columbia V5T 1G4 (CA).(74) Agent: **SALISBURY, Clare** et al.; Gowling WLG (Canada) LLP, 550 Burrard Street, Suite 2300, Bentall 5, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: CYSTEINE ENGINEERED ANTIBODY CONSTRUCTS, CONJUGATES AND METHODS OF USE




FIG. 6




FIG. 6 (cont...)

(57) Abstract: Antibody constructs engineered to introduce at least one cysteine insertion mutation ("cysteine engineered antibody constructs") are described. The inserted cysteine residue(s) may be used as a site for conjugation of one or more active agents to the antibody construct to provide conjugates, such as antibody-drug conjugates.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*